SEARCH

SEARCH BY CITATION

References

  • 1
    Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management – the Genval workshop report. Gut 1999; 44(Suppl.): S116.
  • 2
    Armstrong D, Bennett JR, Blum AL, et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology 1996; 111: 8592.
  • 3
    Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 17280.
  • 4
    Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. Eur J Gastroenterol Hepatol 1998; 10: 11924.
  • 5
    Wiklund I, Bardhan KD, Müller-Lissner S, et al. Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine. Results from a multicentre clinical trial. Ital J Gastroenterol Hepatol 1998; 30: 1927.
  • 6
    Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798810.
  • 7
    Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole Study Investigators. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux ooesophagitis patients: a randomized controlled trial. Aliment Pharmacol Ther 2000; 14: 124958.
  • 8
    Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive oesophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96: 65665.
    Direct Link:
  • 9
    Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive oesophagitis. Am J Gastroenterol 2002; 97: 57583.
    Direct Link:
  • 10
    Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997; 32: 9749.
  • 11
    Bate CM, Booth SN, Crowe JP, et al. Solo Investigator Group. Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux oesophagitis. Gut 1995; 36: 4928.
  • 12
    Venables TL, Newland RD, Patel AC, Hole J, Wilcock C, Turbitt ML. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1997; 32: 96573.
  • 13
    Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. Eur J Gastroenterol Hepatol 1998; 10: 11924.
  • 14
    Galmiche JP, Barthelemy P, Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther 1997; 11: 76573.
  • 15
    Hatlebakk JG, Hyggen A, Madsen PH, et al. Heartburn treatment in primary care: randomised, double blind study for 8 weeks. BMJ 1999; 319: 550553.
  • 16
    Armstrong D, Paré P, Pericak D, Pyzyk M. Symptom relief in gastrooesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive oesophagitis or endoscopy-negative reflux disease. Am J Gastroenterol 2001; 96: 284957.
  • 17
    Lind T, Rydberg L, Kylebäck A, et al. Esomeprazole provides improved acid control versus omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14: 8617.
  • 18
    Thomson ABR, Barkun AN, Armstrong D, et al. The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment – Prompt Endoscopy (CADET-PE) study. Aliment Pharmacol Ther 2003; 17: 148191.
  • 19
    Janssens J, Vantrappen G, Ghillebert G. 24-hour recording of esophageal pressure and pH in patients with noncardiac chest pain. Gastroenterology 1986; 90: 197884.
  • 20
    Vantrappen G, Janssens J, Ghillebert G. The irritable oesophagus – a frequent cause of angina-like pain. Lancet 1987; 1: 12324.
  • 21
    Drossman DA. The functional gastrointestinal disorders and the Rome II process. Gut 1999; 45: 15.
  • 22
    Wiklund I, Carlsson J, Carlsson R, Glise H. Quality of Life as a predictor of treatment response? A meta analysis of clinical trials in patients with heartburn with and without esophagitis. Gastroenterology 1999; 116(Suppl.): A103.
  • 23
    Wiklund I, Butler-Wheelhouse P. Psychosocial factors and their role in symptomatic gastroesophageal reflux disease and functional dyspepsia. Scand J Gastroenterol 1996; 31(Suppl. 220): 94100.
  • 24
    Richter JE, Peura D, Benjamin SB, Joelsson B, Whipple J. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis. Arch Intern Med 2000; 160: 18106.
  • 25
    Johnsson F, Hatlebakk JG, Klintenberg AC, et al. One-week esomeprazole treatment: an effective confirmatory test in patients with suspected gastroesophageal reflux disease. Gastroenterology 2001; 120: A426.
  • 26
    Fass R, Ofman JJ, Sampliner RE, Camargo L, Wendel C, Fennerty MB. The omeprazole test is as sensitive as 24-h oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive oesophagitis. Aliment Pharmacol Ther 2000; 14: 38996.
  • 27
    Schindlbeck NE, Klauser AG, Voderholzer WA, Müller-Lissner SA. Empiric therapy for gastroesophageal reflux disease. Arch Intern Med 1995; 155: 180812.
  • 28
    Schenk BE, Kuipers EJ, Klinkenberg Knol EC, et al. Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol 1997; 92: 19972000.
  • 29
    Röhss K, Hasselgren G, Hedenström H. Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease. Dig Dis Sci 2002; 47: 9548.
  • 30
    Miner P Jr, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and raeprazole: a five-way crossover study. Am J Gastroenterol 2003; 98: 261620.
    Direct Link:
  • 31
    Hunt RH. Importance of pH control in the management of GERD. Arch Intern Med 1999; 159: 64957.
  • 32
    Miner P Jr, Orr W, Filippone J, Jokubaitis L, Sloan S. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol 2002; 97: 13329.
    Direct Link:
  • 33
    Richter JE, Kovacs TOG, Greski Rose PA, Huang B, Fisher R. Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis. Aliment Pharmacol Ther 1999; 13: 795804.
  • 34
    Mathias SD, Colwell HH, Miller DP, Pasta DJ, Henning JM, Ofman JJ. Health-related quality-of-life and quality-days incrementally gained in symptomatic nonerosive GERD patients treated with lansoprazole or ranitidine. Dig Dis Sci 2001; 46: 241623.
  • 35
    Johnsson F, Joelsson B, Gudmundsson K, Greiff L. Symptoms and endoscopic findings in the diagnosis of gastroesophageal reflux disease. Scand J Gastroenterol 1987; 22: 7148.
  • 36
    Schindlbeck NE, Heinrich C, Konig A, Dendorfer A, Pace F, Muller-Lissner SA. Optimal thresholds, sensitivity, and specificity of long-term pH-metry for the detection of gastrooesophageal reflux disease. Gastroenterology 1987; 93: 8590.
  • 37
    Masclee AA, de Best AC, de Graaf R, Cluysenaer OJ, Jansen JB. Ambulatory 24-hour pH-metry in the diagnosis of gastrooesophageal reflux disease. Determination of criteria and relation to endoscopy. Scand J Gastroenterol 1990; 25: 22530.
  • 38
    Johnsson F, Weywadt L, Solhaug JH, Hernqvist H, Bengtsson L. One-week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease. Scand J Gastroenterol 1998; 33: 1520.